Results 151 to 160 of about 103,961 (275)

A Case of Annular Pustular Psoriasis Possibly Triggered by Cabozantinib and Edoxaban During Nivolumab Therapy

The Journal of Dermatology, EarlyView.
Mana Nagatake, Hiroto Horikawa, Risa Kakuta, Takeya Adachi, Keishiro Fukumoto, Masayuki Amagai, Yoshihiro Ito   +6 more
wiley   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy. [PDF]

J Gastric Cancer
Kim HD, Lee H, Lee SY, Lee Y, Hyung J, Moon M, Shin J, Park YS, Ryu MH.   +8 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Immunotherapy-Related Cystitis Induced by Nivolumab for Advanced Gastric Cancer: A Case Report. [PDF]

Case Rep Urol
Arinami K, Ito K, Hasegawa G, Takizawa Y, Ikeda Y, Suda T, Hara N, Nishiyama T.   +7 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). [PDF]

Future Oncol
Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Matilla Peña A, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M.   +27 more
europepmc   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

Fatal Postoperative Interstitial Lung Disease after Neoadjuvant Nivolumab and Complete Resection for Non-Small Cell Lung Cancer: A Case Report. [PDF]

Surg Case Rep
Osako T, Shimamura A, Takuwa T.
europepmc   +1 more source

When Binding Is Not Blockade: Interpreting IgG4+ T Cells After PD‐1 Therapy

Cancer Science, EarlyView.
IgG4 positivity on circulating T cells after PD‐1 therapy may indicate residual antibody binding rather than sustained functional PD‐1 blockade. During sequential ramucirumab plus docetaxel plus G‐CSF treatment, peripheral IgG4+ T‐cell dynamics may also be influenced by redistribution and treatment‐related confounders, limiting direct inference about ...
Man Sun, Dan Zang, Jun Chen
wiley   +1 more source